NCT01839916 · STUDY IN CONTEXT

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Draft scope assessment: unclear. Attached because the study's own record describes refractory disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Percentage of Patients Who Are Able to Receive at Least One DLI Treatment

Source null

→

secondary · POSTED

Time to relapse or death as a result of any cause was evaluated at 2 years and the progression free survival rate was reported.

Patients received at least one DLI Treatment.

→

secondary · POSTED

Computed using the Kaplan-Meier product-limit estimate and expressed as probabilities with a 95% CI.

Patients received at least one DLI Treatment.

→

secondary · POSTED

Estimated by cumulative incidence method.

Patients received at least one DLI Treatment.

→

secondary · POSTED

Estimated by cumulative incidence method.

Patients received at least one DLI treatment.

→

secondary · POSTED

Estimated by cumulative incidence method. Cumulative incidence of treatment-related mortality with relapse of the original disease as the competing risk will be calculated.

Patients received at least one DLI treatment.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id: NCT01839916
trial label: Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
applicability: unclear
applicability note: Attached because the study's own record describes refractory disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0000
source section id
NCT01839916-om-0000
source outcome index
0
endpoint
Percentage of Patients Who Are Able to Receive at Least One DLI Treatment
endpoint definition
Percentage of Patients Who Are Able to Receive at Least One DLI Treatment
time origin
Up to 2 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0001
source section id
NCT01839916-om-0001
source outcome index
1
endpoint
Progression Free Survival (PFS)
endpoint definition
Time to relapse or death as a result of any cause was evaluated at 2 years and the progression free survival rate was reported.
time origin
2 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Patients received at least one DLI Treatment.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0002
source section id
NCT01839916-om-0002
source outcome index
2
endpoint
Overall Survival (OS)
endpoint definition
Computed using the Kaplan-Meier product-limit estimate and expressed as probabilities with a 95% CI.
time origin
At 2 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Patients received at least one DLI Treatment.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0003
source section id
NCT01839916-om-0003
source outcome index
3
endpoint
Rate of Acute GVHD (aGVHD) With Any Grade
endpoint definition
Estimated by cumulative incidence method.
time origin
At 1 year and 2 year
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Patients received at least one DLI Treatment.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0004
source section id
NCT01839916-om-0004
source outcome index
4
endpoint
Rate of Chronic GVHD (cGVHD)
endpoint definition
Estimated by cumulative incidence method.
time origin
At 1 year and 2 year
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Patients received at least one DLI treatment.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0005
source section id
NCT01839916-om-0005
source outcome index
5
endpoint
Treatment-related Mortality
endpoint definition
Estimated by cumulative incidence method. Cumulative incidence of treatment-related mortality with relapse of the original disease as the competing risk will be calculated.
time origin
At 2 year
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Patients received at least one DLI treatment.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0000
arm key
OG000
arm label
Treatment (DLI)
regimen
Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies
analyzed count
77
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01839916-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0001
arm key
OG000
arm label
Treatment (DLI)
regimen
Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies
analyzed count
36
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01839916-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0002
arm key
OG000
arm label
Treatment (DLI)
regimen
Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies
analyzed count
36
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01839916-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0003
arm key
OG000
arm label
Treatment (DLI)
regimen
Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies
analyzed count
36
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01839916-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0004
arm key
OG000
arm label
Treatment (DLI)
regimen
Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies
analyzed count
36
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01839916-om-0004#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
outcome key
om-0005
arm key
OG000
arm label
Treatment (DLI)
regimen
Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies
analyzed count
36
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01839916-om-0005#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-hodgkin-lymphoma-pediatric-refractory-07b44757
nct id
NCT01839916
harm key
EG000
source section id
NCT01839916-ae
event group key
EG000
event group label
Treatment (DLI)
serious affected
12
serious at risk
36
other affected
1
other at risk
36
frequency threshold
0
collection period
2 year
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice